A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.

Hyun Jin ParkGun-Young JangYoung Seob KimJung Hwa ParkSung Eun LeeManh-Cuong VoJe-Jung LeeHee Dong HanIn Duk JungTae Heung KangYeong-Min Park

Published in: Journal for immunotherapy of cancer (2019)

This study therefore proved that human cancer cell-derived RPS3, a novel TLR4 ligand, has great potential as an adjuvant in tumor-specific antigen DC-based vaccines.

Keyphrases

dendritic cells
binding protein
toll like receptor
early stage
immune response
inflammatory response
endothelial cells
papillary thyroid
regulatory t cells
nuclear factor
squamous cell
squamous cell carcinoma
induced pluripotent stem cells